Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13069369 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL13224949 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL13224951 | 1.00 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL14520914 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL13069284 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL6002369 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL6003734 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL6003737 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL14520912 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 | |
| SCHEMBL13224950 | 0.83 | MAOB (0.42) | MAOBMAOALMNASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016053-B1 | PROCESS FOR THE SYNTHESIS OF (+) AND (-)-1-ARYL-3-AZABICYCLO[3.1.0]HEXANES | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | MERCK & CO., INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2007127421-A2 | PROCESS FOR THE SYNTHESIS OF (+) AND (-)-1-ARYL-3-AZABICYCLO[3.1.0]HEXANES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204486-A1 | Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes | ADH1C, AVPR1B, HTR1B | MAOB 14/4885MAOA 156/4885LMNA 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.